Immunotherapy (Issue 2) | Special Reports

The Outlook for CAR-Modified T Cells

March 12, 2014

Clinical Articles

Renier J. Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, discusses the outlook for CAR-modified T cells.

Update on Immunotherapy and Targeted Combination Therapies

March 12, 2014

Clinical Articles

While the concept of cancer-specific immunotherapy is not new, it recently has been proven feasible as a rational treatment for patients with some of the most challenging and difficult malignancies.

How Immunotherapies are Changing the Treatment of Melanoma

March 12, 2014

Clinical Articles

Harriet Kluger, MD, associate professor of medicine (medical oncology), associate director, Hematology/Oncology Fellowship Program, Yale Cancer Center, explains how immunotherapies are changing the treatment of melanoma.

Progress Made With PD-L1 as Predictive Biomarker

March 12, 2014

Clinical Articles

The use of predictive biomarkers in cancer medicine may allow oncologists to target interventions to populations with greater response rates, affect sizes, and benefit-risk ratios.

Oncolytic Viral Therapies About to Spread

March 12, 2014

Clinical Articles

Work on viruses as antitumor agents began in the 1950s, but advances in molecular biology have provided new tools and new possibilities for engineering their potency, selectivity, and safety.

Checking in on Checkpoint Inhibitors

March 12, 2014

Clinical Articles

Survival rates for patients with cancer have consistently increased in past decades. However, a gap remains in treatment options, particularly for patients with a history of treatment for advanced or recurrent solid-tumor cancers.